{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5e8308ce6b0fef1a38c4a215/6a3e9c5b3fba7ccd9cc7513f?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Key questions in FLT3-mutated AML, and ongoing research to address these ","description":"<p>The AML Hub was pleased to speak with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, What are the key ongoing questions in FLT3-mutated AML, and how are ongoing trials addressing these?  </p><p><br></p><p>Craddock begins by highlighting the progress made in the treatment of FLT3-mutated (FLT3m) acute myeloid leukemia (AML) over the past decade with two large randomized clinical trials: the phase III RATIFY (NCT00651261) trial, investigating the addition of midostaurin to standard chemotherapy in patients with newly diagnosed (ND) FLT3m AML; and the phase III QuANTUM-First (NCT02668653) trial, assessing the addition of quizartinib to standard chemotherapy in patients with ND FLT3-internal tandem duplication (FLT3-ITD) AML. He discusses data from trials aiming to further improve outcomes for patients with FLT3m AML and considers whether similar benefit can be demonstrated in patients requiring less intensive regimens. </p><p><br></p><p>This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.</p>","author_name":"Scientific Education Support"}